tradingkey.logo
搜索

HUTCHMED (China) Ltd

HCM
添加自选
11.130USD
+0.360+3.34%
收盘 07-31 16:00美东报价延迟15分钟
1.97B总市值
20.58市盈率 TTM

关于 HUTCHMED (China) Ltd 公司

HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.

HUTCHMED (China) Ltd简介

公司代码HCM
公司名称HUTCHMED (China) Ltd
上市日期May 19, 2006
CEOCheng (Chig Fung)
员工数量1811
证券类型Depository Receipt
年结日May 19
公司地址48th Floor, Cheung Kong Center, 2 Queen's Road Central
城市
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Hong Kong
邮编- -
电话85221281188
网址https://www.hutch-med.com/
公司代码HCM
上市日期May 19, 2006
CEOCheng (Chig Fung)

HUTCHMED (China) Ltd公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--
Dr. Qingmei (May) Wang, Ph.D.
Dr. Qingmei (May) Wang, Ph.D.
Senior Vice President - Business Development and Strategic Alliances
Senior Vice President - Business Development and Strategic Alliances
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Mr. Charles George Rupert Nixon
Mr. Charles George Rupert Nixon
Group General Counsel
Group General Counsel
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Renu Bhatia
Dr. Renu Bhatia
Independent Non-Executive Director
Independent Non-Executive Director
16.00K
--
Ms. Edith Shih
Ms. Edith Shih
Non-Executive Director, Company Secretary
Non-Executive Director, Company Secretary
--
--
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
Acting Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Senior Lead Non-Executive Independent Director
Senior Lead Non-Executive Independent Director
--
--

常见问题

HUTCHMED (China) Ltd的前五大股东是谁?

HUTCHMED (China) Ltd 的前五大股东如下:Dr. Renu Bhatia

有多少机构持有HUTCHMED (China) Ltd(HCM)的股份?

截至2026Q1,共有139家机构持有HUTCHMED (China) Ltd的股份,合计持有的股份价值约为5.33M,占公司总股份的3.05%。与2025Q4相比,机构持股有所增加,增幅为-5943889.00。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有